Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

David Moher, A. Liberati, Jennifer Tetzlaff et al. · BMJ · 2009 · 83.3K citations · Full text

Public Health, Biostatistics, Evidence-based Practice +11

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

David Moher, Alessandro Liberati, Jennifer Tetzlaff et al. · PLoS Medicine · 2009 · 64.1K citations · Full text

Public Health, Biostatistics, Evidence-based Practice +11

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.

David Moher, Alessandro Liberati, Jennifer Tetzlaff et al. · PubMed · 2009 · 45.1K citations · Full text

Nursing, Biostatistics, Evidence-based Practice +10

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak et al. · New England Journal of Medicine · 2001 · 11.5K citations · Full text

Medicine, Oncology, Pharmacology +10

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015 · 6.2K citations · Full text

Medicine, Oncology, Pharmacology +17